IntegraGen, University of Southampton deal

IntegraGen said it partnered with investigators at the university who are leading the open-label, U.K. Phase III New EPOC trial to gain access to data from the trial and publish the results. The trial is comparing chemotherapy alone to chemotherapy in combination with cetuximab in 272 K-Ras ( KRAS)-wild type patients with operable metastases from colorectal cancer. IntegraGen is planning to use the data to validate the cancer biomarker hsa-miR-31-3p, which the company said has shown to be a predictor of progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) treated with anti- EGFR therapy. IntegraGen said the terms of the deal are not disclosed. ...